ENTITY

Ergomed (ERGO LN)

18
Analysis
Health Care • United Kingdom
Ergomed provides specialized services to the pharmaceutical and biotechnology industries, focusing on clinical development, trial management, and pharmacovigilance. The company operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV), offering solutions for all phases of clinical trials and post-approval drug safety. Ergomed was founded in 1997 and is headquartered in Guildford, United Kingdom.
more
bullish•Ergomed
•17 Apr 2023 17:01•Issuer-paid

Ergomed - Solid FY22 marked by broad-based growth

Ergomed reported FY22 results broadly in line with our expectations. Group revenues grew 22.5% y-o-y to £145.3m, underpinned by sustained demand...

Share
bullish•Ergomed
•21 Dec 2022 20:12•Issuer-paid

Ergomed - Exiting FY22 on a strong footing

In the run-up to Ergomed’s FY22 trading update (expected end-January 2023), we take a fresh look at our estimates for the company and make minor...

Share
bullish•Ergomed
•18 Nov 2022 20:43•Issuer-paid

Ergomed - Two key management changes

In a strategic move to support its business development plans and digitisation efforts, Ergomed has announced two senior appointments to its...

Share
bullish•Ergomed
•30 Sep 2022 16:22•Issuer-paid

Ergomed - Poised for a strong FY22

Ergomed released full H122 accounts following its July 2022 trading update, the key takeaway of which was the sustained strong momentum across both...

Share
bullish•Ergomed
•27 Jul 2022 22:46•Issuer-paid

Ergomed - Sustained growth momentum in H122

Ergomed’s H122 trading update re-emphasised its robust business model and resilient growth despite the challenging macro environment. Revenues grew...

Share
x